The foundation Stichting Eigen Regie,kvk 70567573 was established on januari 8 th 2018.                               It's core activities were wound management.This came to a hold in 2020 during Covid-19.It's expertise led to the development of new antibiotics.                       As a start-up,Beneluxbio does its own in-house research and has licensed compounds from Liberpharma.                         Liberpharma became in 2022 the trading name of the Stichting Eigen Regie.
With a commitment to innovation and patient care, we aim to develop new medicines that address infectious diseases and myoblastoma,multiple myeloma ( via molecular glues)                                               Many compounds were designed and developed under a program of the NCI
Director is mr. J.H.A.Cornelesen
We are gratefull to our former director mr. R.G.Dassen ( Itteren,Netherlands)for his relentless commitment to the Stichting Eigen Regie